Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
about
Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countriesEfficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.Nintedanib for the treatment of idiopathic pulmonary fibrosis.Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.Update in Interstitial Lung Disease 2016.Idiopathic pulmonary fibrosis: pathogenesis and management.Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.Idiopathic Pulmonary Fibrosis (IPF): An OverviewEfficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosisSafety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practiceQuantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacityNintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experienceInvestigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trialInterpretation of HRCT Scans in the Diagnosis of IPF: Improving Communication Between Pulmonologists and Radiologists
P2860
Q38598382-307DC74B-6572-408C-9BAF-3F5EC762EAF7Q39344375-8190A9C0-3CC8-45E0-9A21-B375CD06C8D2Q41151927-8ECC7E24-069E-4D82-8567-F20876CDA535Q41712176-BFE09AE2-B661-4114-A393-3FB8D29C9894Q47361127-30A90587-BF69-48DA-AC67-A8997396786AQ47658514-315777E6-1470-45BE-B0F6-9A9FA9CD13B5Q47791471-A58D8AAC-6E8D-41C6-BD07-3FA17FA1807AQ48164431-D4AC35A1-618C-446E-9D43-D7813C8DE5E0Q49734357-B18D8EAA-B410-4241-9033-B73FA9A445EFQ50326794-93BF64A0-7FE4-49AC-94A7-1463F9C711D0Q55135908-E10FBA56-191F-4027-B1BD-E0C8BF558CEEQ57170607-4DC8669C-E778-4C26-97F6-923351BBE79AQ57811298-4E30BC6C-731E-4285-89F9-C39BFE9B3C9AQ58587321-D55DB313-57D0-4247-B1DC-4855D9749899Q58608704-678317AD-CE1D-4DCD-B9A1-BA799294D972Q58698965-A1CF1CDB-EAFD-48A9-9D37-E7D1DC4C570EQ58735224-4FC8C9E3-6B5C-4ADF-8775-FFEA8DA74AF3Q58788821-B2AF7A16-F1A9-4571-B995-2D7E6ECE98EA
P2860
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
@en
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
@nl
type
label
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
@en
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
@nl
prefLabel
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
@en
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
@nl
P2093
P2860
P1433
P1476
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
@en
P2093
Christoph Hallmann
Jürgen Behr
Martin Kolb
Roland M du Bois
Susanne Stowasser
Wenbo Tang
P2860
P304
P356
10.1136/THORAXJNL-2016-208710
P407
P577
2016-09-26T00:00:00Z